ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULT PATIENTS WITH IDH MUTATED AML AND MDS: A STUDY FROM THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR

被引：0
|
作者：
Perez-Gonzalez, Ana [1 ]
Navarro, Victor [2 ]
Guerreiro, Manuel [3 ]
Delgado, Izarbe [4 ]
Pilar Gonzalez, Ana [5 ]
Avendano, Alejandro [6 ]
Musseti, Alberto [7 ]
Kwon, Mi [8 ]
Garcia Cadenas, Irene [9 ]
Zudaire Ripa, Maria Teresa [10 ]
Lopez Godino, Oriana [11 ]
Valcarcel Ferreiras, David [1 ]
Orti Pascual, Guillermo [1 ]
机构：
[1] Univ Hosp Vall dHebron, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Oncol Data Sci ODysSey Grp, Barcelona, Spain
[3] Univ Hosp La Fe, Valencia, Spain
[4] Univ Hosp Arnau Vilanova, Lleida, Spain
[5] Univ Hosp Cabuenes, Gijon, Spain
[6] Univ Hosp Sala manca, Salamanca, Spain
[7] Hosp Duran Reynals, Inst Catala Oncol, Barcelona, Spain
[8] Univ Hosp Gregorio Maranon, Madrid, Spain
[9] Univ Hosp Santa Creu & St Pau, Barcelona, Spain
[10] Complejo Hosp Navarra, Pamplona, Spain
[11] Univ Hosp Morales Meseguer, Murcia, Spain
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P005
引用
收藏
页码：156 / 157
页数：2
相关论文
共 27 条
  • [21] Acute Myeloid Leukemia (AML) Patients with Myelodysplasia (MDS) Related-Gene Mutations in First Complete Remission (CR1) Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplant (HCT)
    Sayyed, Ayman
    Kim, Taehyung Simon
    Park, Silvia
    Ahn, Jae-Sook
    Karsan, Aly
    Gagnon, Marie-France
    Bergeron, Julie
    Kim, Hee-Je
    Kim, Hyeoung-Joon
    Sanford, David
    Schuh, Andre C.
    Kim, Dennis Dong Hwan
    BLOOD, 2023, 142
  • [22] Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia Transformed from Ph-Negative Myeloproliferative Neoplasm: A Study from the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation (JS']JSHCT)
    Takagi, Shinsuke
    Masuoka, Kazuhiro
    Uchida, Naoyuki
    Kurokawa, Mineo
    Nakamae, Hirohisa
    Tsudo, Mitsuru
    Iwato, Koji
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Takami, Akiyoshi
    BLOOD, 2014, 124 (21)
  • [23] Outcome and Prognostic Index for Reduced-Intensity Allogeneic Stem Cell Transplantation (RIST) for Elderly Patients with De Novo Acute Myeloid Leukemia (AML): A Study From the AML Working Group of the Japan Society for Hematopoietic Cell Transplantation (JS']JSHCT)
    Kanamori, Heiwa
    Fukuda, Takahiro
    Taniguchi, Shuichi
    Sawa, Masashi
    Kondo, Tadakazu
    Miyamura, Koichi
    Kobayashi, Naoki
    Kobayashi, Hikaru
    Morishima, Yasuo
    Hirokawa, Makoto
    Atsuta, Yoshiko
    Takami, Akiyoshi
    BLOOD, 2012, 120 (21)
  • [24] Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CRI) Post Induction Chemotherapy: a Retrospective Case Control Study.
    Efebera, Yvonnr A.
    Kantarjian, Hagop M.
    Andersson, Borje
    Pierce, Sherry
    Silva, Leandro De Padua
    Ravandi, Farhad
    Giralt, Sergio A.
    Borthalcur, Gautain
    Champlin, Richard
    De Lima, Marcos
    BLOOD, 2008, 112 (11) : 411 - 411
  • [25] Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee
    Sobecks, Ronald M.
    Gallagher, Meighan M.
    Askar, Medhat
    Haagenson, Michael D.
    Wang, Tao
    Spellman, Stephen
    Lee, Stephanie J.
    Vina, Marcelo A. Fernandez
    Muller, Carlheinz R.
    Verneris, Michael R.
    Woolfrey, Ann E.
    Shaw, Peter J.
    Weisdorf, Daniel J.
    Cooley, Sarah
    Miller, Jeffrey S.
    Hsu, Katharine C.
    BLOOD, 2013, 122 (21)
  • [26] Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)
    Schroeder, Thomas
    Czibere, Akos
    Kroeger, Nicolaus
    Platzbecker, Uwe
    Bug, Gesine
    Uharek, Lutz
    Luft, Thomas
    Wolschke, Christine
    Bruns, Ingmar
    Zohren, Fabian
    Fenk, Roland
    Haas, Rainer
    Kobbe, Guido
    BLOOD, 2011, 118 (21) : 300 - 300
  • [27] Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat
    Pagel, John M.
    Othus, Megan
    Garcia-Manero, Guillermo
    Fang, Min
    Radich, Jerald P.
    Rizzieri, David A.
    Marcucci, Guido
    Strickland, Stephen A.
    Litzow, Mark
    Savoie, Mary Lynn
    Spellman, Stephen R.
    Confer, Dennis L.
    Chell, Jeffrey
    Brown, Maria
    Medeiros, Bruno C.
    Sekeres, Mikkael A.
    Lin, Tara L.
    Uy, Geoffrey L.
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Larson, Richard A.
    Stone, Richard M.
    Claxton, David F.
    Essell, James
    Luger, Selina
    Mohan, Sanjay R.
    Moseley, Anna
    Erba, Harry P.
    Appelbaum, Frederick R.
    BLOOD, 2016, 128 (22)
123